U.S. Markets open in 4 hrs 5 mins
  • S&P Futures

    3,937.50
    -7.50 (-0.19%)
     
  • Dow Futures

    33,596.00
    -37.00 (-0.11%)
     
  • Nasdaq Futures

    11,531.75
    -34.25 (-0.30%)
     
  • Russell 2000 Futures

    1,811.70
    -2.40 (-0.13%)
     
  • Crude Oil

    73.16
    -1.09 (-1.47%)
     
  • Gold

    1,786.10
    +3.70 (+0.21%)
     
  • Silver

    22.50
    +0.16 (+0.72%)
     
  • EUR/USD

    1.0496
    +0.0027 (+0.2624%)
     
  • 10-Yr Bond

    3.5130
    0.0000 (0.00%)
     
  • Vix

    22.47
    +1.72 (+8.29%)
     
  • GBP/USD

    1.2152
    +0.0018 (+0.1507%)
     
  • USD/JPY

    137.4350
    +0.4750 (+0.3468%)
     
  • BTC-USD

    16,822.27
    -159.98 (-0.94%)
     
  • CMC Crypto 200

    394.73
    -7.07 (-1.76%)
     
  • FTSE 100

    7,510.37
    -11.02 (-0.15%)
     
  • Nikkei 225

    27,686.40
    -199.47 (-0.72%)
     

Incyte to acquire North Carolina drug developer in deal valued at up to $1.36 billion

Incyte to acquire North Carolina drug developer in deal valued at up to $1.36 billion

Wilmington biotech company Incyte has agreed to acquire Villaris Therapeutics in a deal valued at up to $1.36 billion. The centerpiece of the deal is auremolimab, a monoclonal antibody that is under development to treat the skin disorder vitiligo — but has potential applications beyond dermatology. Villaris, based in Cary, North Carolina, was founded in 2019 and is backed by Medicxi, a health care-focused investment firm based in London.